DGAP-Adhoc

Biotest AG: Biotest increases revenues significantly by 16.2%

Biotest AG / Key word(s): Preliminary Results

13.02.2015 10:59

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad-hoc RELEASE
Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)

Biotest increases revenues significantly by 16.2%

Dreieich, 13. February 2015. According to preliminary and unaudited
figures, the Biotest Group increased revenues to EUR 582.0 million. This
represents an increase of 16.2% compared to the previous year (EUR 500.8
million). Biotest successfully gained market shares - particularly in the
Middle and Far East.

On account of advanced research and development cost, additional expenses
relating to the planed production capacity expansion at the headquarters in
Dreieich, Germany, as well as overall lower margin business, especially in
crisis regions, Group's earnings before interest and tax (EBIT) came in at
EUR 53.4 million at the previous year EBIT level (EUR 53.8 million).

Biotest will publish final results for the Financial Year 2014 and the
annual report on March 24th, 2015. The Annual General Meeting of Biotest AG
will take place on May 7th, 2015 in Frankfurt am Main, Germany.

Biotest Aktiengesellschaft
Board of Management

Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.de

Disclaimer

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
clinical immunology, haematology and intensive medicine. Biotest develops
and markets immunoglobulins, coagulation factors and albumins based on
human blood plasma. These are used for diseases of the immune and
haematopoietic systems. In addition Biotest develops monoclonal antibodies
in the indications of rheumatoid arthritis and cancer of plasma cells,
which are produced by recombinant technologies. Biotest has more than
2.100 employees worldwide. The preference shares of Biotest AG are listed
in the SDAX on the Frankfurt stock exchange.
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart


13.02.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: [e-mail]
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------